| Description | This is a human ADCC antibody that targets human LILRB4. The MAb has demonstrated strong effectiveness in inhibiting the growth of monocytic AML in different models, such as patient-derived xenograft (PDX) mice and syngeneic immunocompetent AML mice. Additionally, it has been found that the MAb enhances the effectiveness of chemotherapy treatment by promoting the movement of leukemia cells. This antibody has potential applications in anti-cancer therapies. It effectively prevents AML cell migration and tissue infiltration. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Block; ADCC |
| Application Notes | The EC₅₀ value for the mAb binding to LILRB4 is 0.23 nM as determined by ELISA. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | LILRB4 |
| Alternative Name | ILT3; LIR5; CD85K; ILT-3; LIR-5; leukocyte immunoglobulin-like receptor subfamily B member 4; CD85 antigen-like family member K; immunoglobulin-like transcript 3; leucocyte Ig-like receptor B4; leukocyte immunoglobulin-like receptor 5; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4; monocyte inhibitory receptor HM18 |
| Gene ID | 11006 |
| UniProt | Q8NHJ6 |
| Research Area | Immunology |
